Skip to content
Catalyst

PapersPMID:20216298

Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.

AIDS (London, England)2010The record ↗

  1. Finding, moderate evidenceraisesHDL cholesterol

What moved

1 findingHow to read these marks →
  • Increases HDL cholesterol

    moderatereplicated ×2

    “After 12 weeks, participants receiving ERN had a median HDL-c (interquartile range) increase of 3.0 mg/dl (0.75 to 5.0) compared with −1.0 mg/dl in controls (−6.0 to 2.5), P value is equal to 0.04.”
    Study
    RCT
    Duration
    3 months
    Dose studied
    extended-release niacin (Niaspan) starting at 500 mg per night, titrated to a maximum tolerated dose not exceeding 1500 mg per night
    Population
    HIV-1-infected adults on stable antiretroviral therapy with low HDL-c (below 40 mg/dl) and LDL-c below 130 mg/dl, no statins or fibrates; randomised to extended-release niacin or an untreated control arm (no placebo)

Study record

Design
randomised controlled trial
Species
human
Population
HIV-infected adults on stable HAART with low HDL-c
Participants
19
Comparator
no treatment
Duration
84 days
Endpoints measured
6